What is the trade name of Trientin sold in the Chinese market?

In the Chinese market, Trientine (Trientine) is a copper chelation treatment drug for Wilson's disease. Its trade name is not widely registered and circulated across the country. Instead, it mainly enters the country as an original brand through specific import channels. Currently, this drug is mainly introduced through the franchise policy of Hainan Boao Lecheng International Medical Tourism Pilot Zone. The original product name is Cuprior, which is a trientine tetrahydrochloride preparation developed by Orphalan Company.

The introduction of trientine is a milestone for Chinese patients with Wilson's disease. Due to the limited types of drugs for the treatment of Wilson's disease in China, penicillamine has been the main drug for a long time. However, the incidence of adverse reactions of penicillamine is high, making it difficult for many patients to insist on long-term use. As a widely used alternative drug to penicillamine in the world, trientine has become one of the treatment options recommended by many medical centers because it does not contain sulfhydryl groups, is less allergic, and has better tolerance.

Although Trientine has been introduced through the Hainan Lecheng franchise policy, it has not yet received full drug registration approval in other provinces and cities in mainland China, and therefore cannot be purchased through regular hospital pharmacies or the medical insurance system. Patients need to go to a specific medical institution in Hainan Lecheng for evaluation and obtain medication qualifications under the guidance of a doctor. This "regional franchised marketing" model has filled the treatment gap in the domestic market to a certain extent, but it also limits the popularity of drugs.

In terms of commodity prices, since trientine is an imported original drug, its pricing is relatively high. Taking the current international market as a reference, the annual treatment cost of trientine is much higher than that of penicillamine. Therefore, patients who use trientine in China mostly pay for it at their own expense, which imposes a heavy financial burden. Nonetheless, as domestic policies on rare diseases are gradually improved and the imported drug approval mechanism becomes increasingly efficient, trientine is expected to enter the national drug approval system in the future, further lowering the threshold and cost.

Reference materials:https://www.cufence.com/